Unclaimed brand
Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and improving efficacy by increasing lung exposure. Our lead candidate, AP01, is an optimized inhaled formulation of pirfenidone, currently being studied for progressive pulmonary fibrosis in the Phase 2b MIST study. In addition, we completed two Phase 1 studies for AP02, an optimized inhaled formulation of nintedanib. At Avalyn, we are driven by our mission to empower lives through breakthrough inhaled therapies for interstitial lung diseases, turning breathlessness into hope.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#31CDCF
Turquoise
49, 205, 207
181, 62, 50
76, 1, 0, 19
#F9F9F9
Alabaster
249, 249, 249
0, 0, 98
0, 0, 0, 2
#006BA1
Allports
0, 107, 161
200, 100, 32
100, 34, 0, 37
Avalyn Pharma Inc. is a clinical-stage biotechnology company focused on developing inhaled therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Its approach is to deliver established medicines directly to lung tissue through inhaled formulations, with the aim of potentially improving efficacy while avoiding side effects associated with systemic drug delivery.
The company’s pipeline includes two clinical-stage programs: AP01, an inhaled formulation of pirfenidone, and AP02, an inhaled formulation of nintedanib. Its preclinical program, AP03, combines inhaled pirfenidone and nintedanib in a fixed-dose formulation. Avalyn’s work is supported by a leadership team with expertise in inhaled drug development.
The company shares scientific and clinical information through publications, patient and scientific resources, and updates on its research. Its website also provides information about clinical trials, expanded access, and opportunities for patients, care partners, and potential partners to engage with its work. Avalyn’s focus is on advancing lung-targeted treatment options for people affected by serious rare lung diseases
